Skip to main content

$0.049 0.007 (16.67%)

High

$0.05

Low

$0.04

Trades

74

Turnover

$48,318

Volume

1,094,468
30 June 2023 at 4:10pm
Register to track PXS and receive email alerts.
Subject
PXS Ann: Chairman's Address to Shareholders

PXS Ann: Investor Presentation - September Quarterly Update

PXS Ann: Quarterly Activities Report

PXS Ann: Appendix 4C Cash Flow Report

PXS Ann: Pharmaxis Quarterly Shareholder Update and Investor Briefing

PXS Ann: PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial

PXS Ann: PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial

PXS Ann: Corporate Governance Statement

PXS Ann: Appendix 4G

PXS Ann: Notice of Annual General Meeting/Proxy Form

PXS Ann: Annual Report to shareholders

PXS Ann: Change in substantial holding

PXS Ann: Change in substantial holding

PXS Ann: Pharmaxis to Present at Biotech Webinar

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Notification of cessation of securities - PXS

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Investor Presentation

PXS Ann: Pharmaxis Treatment to Prevent Wound and Burns Scars Clears

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Application for quotation of securities - PXS

PXS Ann: PXS Grants Exclusive Option to Develop High Payload Inhaler

PXS Ann: Notification regarding unquoted securities - PXS

PXS Ann: Proposed Issue of Employee Options

PXS Ann: Change of Director's Interest Notice

PXS Ann: Notification of cessation of securities - PXS

PXS Ann: Preliminary Final Report

PXS Ann: PXS Drug Decreases Tumour Burden in Liver Cancer Model

PXS Ann: PXS Commences Final Cohort Dosing in Phase 1c Cancer Trial

PXS Ann: Investor Presentation Quarterly Shareholder Update

PXS Ann: Quarterly Activities/Appendix 4C Cash Flow Report

PXS Ann: Quarterly Activities/Appendix 4C Cash Flow Report

PXS Ann: Pharmaxis Shareholder Investor Call - Corrected Link

PXS Ann: Pharmaxis Quarterly Shareholder Investor Briefing

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Application for quotation of securities - PXS

PXS Ann: PXS Sells Australian Distribution Rights for A$2m

PXS Ann: BTC: Exclusive distribution rights for Bronchitol & Aridol

PXS Ann: Notification of cessation of securities - PXS

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Change in substantial holding

PXS Ann: PXS Announces First Results in Bone Marrow Cancer Trial

PXS Ann: Change of Director's Interest Notice

PXS Ann: Progression of Clinical Trial in Bone Marrow Cancer

PXS Ann: Investor Presentation - 4 June 2021

PXS Ann: Pharmaxis Investor Briefing

PXS Ann: Change of Director's Interest Notice

PXS Ann: Promising New Drug to Tackle Brain Cancer

PXS Ann: Quarterly Activity Report

Register to track PXS and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL